Terzepitide
Terzepitide is a combined GLP-1 and GIP agonist.
Terzepitide has the same indications and precautions as Semaglutide. It often results in greater weightlloss than Semaglutide. Terzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, providing a synergistic effect that may enhance glycemic control and weight loss compared to semaglutide, which primarily targets the GLP-1 receptor.
Terzepatide and semaglutide are both glucagon-like peptide-1 (GLP-1) receptor agonists used primarily for managing type 2 diabetes and promoting weight loss. However, terzepatide offers several advantages over semaglutide.
Clinical trials suggest that terzepatide may lead to more significant weight reduction than semaglutide, making it an appealing option for patients focused on weight management. Terzepatide may result in better HbA1c reductions than semaglutide, particularly in certain populations with type 2 diabetes.
Early research suggests that terzepatide might offer cardiovascular benefits, although more studies are needed to confirm this.